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In Brief
Kilpatrick et al. have used
bioluminescence resonance energy
transfer (BRET) and VEGFR2 tagged with
NanoLuc luciferase, to demonstrate that
oligomeric complexes involving VEGFR2
and b2-adrenoceptors can be generated
in both cell membranes and intracellular
endosomes. These complexes are
agonist sensitive and retain their ability to
couple to intracellular signaling proteins.
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Vascular endothelial growth factor (VEGF) is an impor-
tant mediator of endothelial cell proliferation and
angiogenesis via its receptor VEGFR2. A common
tumor associated with elevated VEGFR2 signaling
is infantile hemangioma that is caused by a rapid pro-
liferation of vascular endothelial cells. The current
first-line treatment for infantile hemangioma is the
b-adrenoceptor antagonist, propranolol, although its
mechanism of action is not understood. Here we
have used bioluminescence resonance energy trans-
fer and VEGFR2 genetically tagged with NanoLuc
luciferase to demonstrate that oligomeric complexes
involving VEGFR2 and the b2-adrenoceptor can be
generated in both cell membranes and intracellular
endosomes.Thesecomplexesare inducedbyagonist
treatment and retain their ability to couple to intracel-
lular signaling proteins. Furthermore, coupling of b2-
adrenoceptor to b-arrestin2 is prolonged by VEGFR2
activation. These data suggest that protein-protein
interactions between VEGFR2, the b2-adrenoceptor,
and b-arrestin2 may provide insight into their roles in
health and disease.
INTRODUCTION
Vascular endothelial growth factor A (VEGF-A) is an important
mediator of endothelial cell proliferation and angiogenesis (Fer-830 Cell Chemical Biology 26, 830–841, June 20, 2019 ª 2019 The A
This is an open access article under the CC BY license (http://creativerara, 2009; Shibuya, 2011; Musumeci et al., 2012). VEGF-A
mediates its effects on endothelial cells predominantly via the re-
ceptor tyrosine kinase (RTK) VEGF receptor 2 (VEGFR2), which
also represents an important drug target for cancer angiogenesis
(Ferrara, 2009; Claesson-Welsh and Welsh, 2013; Peach et al.,
2018a). VEGFR2 signaling is elevated in infantile hemangioma
due to the rapid proliferation of vascular endothelial cells during
early infancy (Ou et al., 2014). The current first-line treatment for
infantile hemangioma is the b-adrenoceptor antagonist, pro-
pranolol, although its mechanism of action is not fully under-
stood (Le´aute´-Labre`ze et al., 2008; Ozeki et al., 2016; Stiles
et al., 2012; Mulcrone et al., 2017). The therapeutic effect of pro-
pranolol is mediated by antagonism of the b2-adrenoceptor (a G
protein-coupled receptor [GPCR]) and appears to result from
reduced VEGF-A expression and cell proliferation (Ozeki et al.,
2016; Stiles et al., 2012; Mulcrone et al., 2017; Park et al.,
2011). b2-Adrenoceptor activation has also been reported to
play a critical role in mediating stress-induced metastasis in
breast cancer (Mulcrone et al., 2017; Sloan et al., 2010; Chang
et al., 2016) and cancer angiogenesis in prostate cancer (Hulsur-
kar et al., 2017). For example, skeletal colonization by breast
cancer cells is stimulated by a b2-adrenoceptor- and VEGF-
dependent neo-angiogenic switch (Mulcrone et al., 2017).
In addition toGPCRagonists eliciting changes in theexpression
of growth factors (such as VEGF-A), there is accumulating evi-
dence for complex interactions between their cognate receptors
(Luttrell et al., 1999; George et al., 2013; Pyne and Pyne, 2011;
Liebmann, 2011). Three different mechanisms of GPCR-RTK
interaction have been identified: (1) GPCR activation of matrix
metalloproteases leading to the shedding of heparin-binding
growth factors (e.g., heparin-binding epidermal growth factor)
and the subsequent activation of their receptors (Daub et al.,uthor(s). Published by Elsevier Ltd.
commons.org/licenses/by/4.0/).
Figure 1. Using NanoBRET to Characterise
the Formation of VEGFR2 Homodimers
and Ligand Binding at VEGFR2
(A) Schematic representation of the use of
NanoBRET to investigate the interaction be-
tween NLuc-tagged VEGFR2 (NLuc-VEGFR2) and
HaloTag-VEGFR2, or the binding of a fluorescent
analog of VEGF165a to NLuc-VEGFR2.
(B) NanoBRET saturation binding curves ob-
tained for VEGF165a-TMR binding to NLuc-tagged
VEGFR2. HEK293 cells stably transfected with
NLuc-VEGFR2 were treated for 60 min with
increasing concentrations of VEGF165a-TMR (filled
circles). Non-specific binding (open circles) was
determined in the presence of 10 nM VEGF165a.
Values are means ± SEM from four separate
experiments each performed in triplicate. pKD of
VEGF165a-TMR was 9.00 ± 0.16 (n = 4).
(C) BRET experiments investigated the constitutive
and ligand-induced dimerization of VEGFR2.
HEK293 cells were transiently transfected with a
fixed concentration of donor NLuc-VEGFR2 cDNA
(0.05 mg/well) and increasing concentrations of
acceptor HaloTag-VEGFR2 cDNA. Cells were
treated with either vehicle (open circles) or 1 nM
VEGF165a (filled circles) for 60 min at 37
C. Dupli-
cate measurements were made for each condition
in each individual experiment and values shown are the means ± SEM obtained in seven separate experiments. *p < 0.05; **p < 0.001; student’s t test.
(D) HEK293T cells were transiently transfected with 0.05 mg/well HaloTag VEGFR2 cDNA and 0.025 mg/well of NLuc-VEGFR2 cDNA and treated with
increasing concentrations of VEGF165a for 60 min at 37
C. Values are means ± SEM obtained in six separate experiments.1997; Prenzel et al., 1999; Hart et al., 2005); (2) GPCR mediated
transactivation and phosphorylation of RTKs following activation
of intracellular signaling cascades (Luttrell et al., 1999; Thuringer
et al., 2002; Zajac et al., 2011); and (3) GPCR-RTK oligomerization
(Liebmann, 2011; Bergelin et al., 2010). With respect to receptor
oligomerization, it iswell established thatRTKsexist aspreformed
dimers or can be induced to dimerize following the binding of their
cognate ligand (Bessman et al., 2014a; 2014b; Freed et al., 2015).
Studies with purified extracellular domains of VEGFR2 have pro-
vided evidence for VEGF-A-induced homodimerization (Dosch
and Ballmer-Hofer, 2010; Brozzo et al., 2012; Markovic-Mueller
et al., 2017). However, recent work has also suggested that
VEGFR2 can form dimers in the absence of VEGF (Sarabipour
et al., 2016). Furthermore, signaling complexes have been re-
ported between VEGFR2 and the GPCR sphingosine-1-phos-
phate receptor in thyroid carcinoma cells (Bergelin et al., 2010).
This raises the prospect that VEGFR2 may form oligomeric com-
plexeswith b2-adrenoceptors and provide a potential mechanism
ofaction for the therapeutic benefit ofpropranolol in hemangioma.
Here we have used bioluminescence resonance energy trans-
fer (BRET) with VEGFR2 genetically tagged with the NanoLuc
(NLuc) luciferase (Stoddart et al., 2015; 2018; Kilpatrick et al.,
2017) to investigate complex formation between VEGFR2 and
the b2-adrenoceptor in living cells.
RESULTS
Constitutive and VEGF165a-Induced VEGFR2
Homodimerization
To monitor ligand binding and receptor dimerization of VEGFR2
using BRET, we tagged VEGFR2 on its N terminuswith the bright,small (19.1 kDa) NLuc luciferase (Stoddart et al., 2015; Kilpatrick
et al., 2017; Peach et al., 2018b) (see scheme in Figure 1A). Use of
a fluorescent analog of VEGF165a enabled ligand binding to be
monitored by NanoBRET in HEK293 cells stably expressing
NLuc-VEGFR2 (Figure 1B), and to demonstrate that the NLuc-
tagged VEGFR2 retains its high affinity for VEGF165a (Figure S1A).
We were also able to show that constitutive VEGFR2 dimers are
formed in HEK293 cells by co-transfecting cells with NLuc-
VEGFR2 and anN-terminal HaloTag-labeled VEGFR2 (Figure 1C).
In these experiments HEK293 cells were transiently transfected
with a fixed concentration of donor NLuc-VEGFR2 cDNA and
increasing concentrations of acceptor HaloTag VEGFR2 cDNA.
The BRET signal clearly saturated (as would be expected for a
specific protein-protein interaction [Mercier et al., 2002]) and
then began to decrease at the highest HaloTag VEGFR2 cDNA
concentration used, probably due to the concentration of protein
not being linearly related to cDNA concentration at high amounts.
Importantly, these effects were significantly enhanced when cells
were treated with 1 nM VEGF165a for 60 min at 37
C (Figure 1C).
Analysis of the effect of increasing concentrations of VEGF165a on
the homodimerization obtained when 0.05 mg/well HaloTag
VEGFR2 cDNA was transiently transfected with 0.025 mg/well of
NLuc-VEGFR2 cDNA showed a clear saturable effect with a half
maximal effective concentration (pEC50;log EC50) for VEGF165a
of 8.81 ± 0.20 (n = 6; Figure 1D). A similar effect was observed
when 0.05mg/well HaloTag VEGFR2 cDNA was transiently
transfected into a stable NLuc-VEGFR2 cell line (Kilpatrick
et al., 2017) yielding a pEC50 for VEGF165a of 9.40 ± 0.28
(n = 4). These values are very similar to the binding affinity of
VEGF165a determined from NanoBRET binding (pKi = 10.17 ±
0.09, n = 7; Figure S1A) and to the pEC50 values for VEGF165aCell Chemical Biology 26, 830–841, June 20, 2019 831
Figure 2. BRET Experiments Investigating
GPCR Homo-Dimerization and Complex
Formation between GPCRs and VEGFR2
(A and B) GPCR homodimer formation was investi-
gated using transient transfection with NLuc-GPCR
cDNA (0.05 mg/well) and increasing concentrations
of SNAP-tagged GPCR cDNA for (A) the b2-adre-
noceptor (b2-AR) or (B) the adenosine A3-receptor
(A3R). Data are means ± SEM from five separate
experiments, each performed in duplicate.
(C andD)Complex formation between VEGFR2 and
GPCRs. HEK293 cells were transfected with NLuc-
VEGFR2 cDNA (0.05 mg/well) and increasing con-
centrations of SNAP-taggedGPCRcDNA for (C) the
b2-adrenoceptor or (D) the adenosine A3-receptor.
Data are means ± SEM from five separate experi-
ments, each performed in duplicate.obtained using an NFAT reporter assay in cells expressing either
NLuc-VEGFR2 or HaloTag-VEGFR2 (9.50 ± 0.06 and 10.00 ± 0.14
for NLuc-VEGFR2 and HaloTag-VEGFR2, respectively; n = 5 in
each case; Figure S1B). These values were also similar to those
previously reported for the wild-type VEGFR2 (pEC50 = 9.66 ±
0.05 [Carter et al., 2015]) and confirm that the N-terminal NLuc
and HaloTag labels do not interfere with intracellular signaling
or binding of VEGF165a.
VEGFR2-GPCR Oligomeric Complexes
It is well established that many GPCRs can form homodimers
(Ferre´ et al., 2014; Vischer et al., 2015; Parmar et al., 2016).
Here, we have used transient expression of NLuc- and SNAP-
taggedGPCRpairs to demonstrate that the twoGPCRs (b2-adre-
noceptor and adenosine A3 receptors) studied here can form
homodimers that are detectable using BRET (Figures 2A and
2B). Transient transfection of donor NLuc-tagged GPCR cDNA
and increasing concentrations of acceptor SNAP-tagged GPCR
cDNA revealed a clear and statistically significant saturation of
the BRET signal that was consistent with a specific protein-pro-
tein interaction (Figures 2A and 2B; Table S1). When NLuc-
VEGFR2 cDNA was co-transfected with SNAP-tagged GPCR
cDNA, evidence for a selective interaction with b2-adrenoceptors
was revealed (Figure 2C; Table S1). Clear saturation of the BRET
signal was observed that was in keeping with close proximity
(<10 nm [Mercier et al., 2002]) between VEGFR2 and the b2-adre-
noceptor (Figure 2C). Given the propensity for both VEGFR2 and
the b2-adrenoceptor to form homodimers, this may represent the832 Cell Chemical Biology 26, 830–841, June 20, 2019formation of a larger oligomeric complex.
In marked contrast, no evidence for a
specific interaction between VEGFR2
and the adenosine A3 receptor was
observed (Figure 2D). The BRET signal
increased linearly with increasing concen-
tration of acceptor SNAP-tagged adeno-
sine A3-receptor cDNAwhich is consistent
with a non-specific interaction caused
by bystander BRET (Figure 2D) (Mercier
et al., 2002). A comparison of the expres-
sion level of SNAP-tagged b2-adrenocep-
tors and adenosine A3 receptors in thesetransient transfection experiments confirmed that very similar
levels of expression of the two GPCRswere achieved in the pres-
ence of NLuc-VEGFR2 (Figure S2).
A study of the impact of agonist stimulation on the formation of
VEGFR2-b2-adrenoceptor complexes (Figure 3) indicated that
there was a significant concentration-dependent enhancement
of VEGFR2-b2-adrenoceptor complex formation induced by
either VEGF165a or isoprenaline (Figures 3C and 3D). Interestingly,
in cells transfected with both VEGFR2 and b2-adrenoceptor
cDNA, VEGF165a was still able to stimulate VEGFR2 dimerization
and both basal and VEGF-stimulated VEGFR2 homodimeri-
zation was unaffected by co-stimulation with isoprenaline
(Figures 3E and 3G). Similarly, VEGF165a (Figure 3F) and isopren-
aline treatment (Figure 3H) did not alter b2-adrenoceptor
homodimerization.
To ensure that VEGFR2-b2-adrenoceptor oligomeric com-
plexes were not a result of receptor overexpression, we took
advantage of the endogenously expressed b2-adrenoceptors
in HEK293 cells. Using CRISPR/Cas9 genome-engineering,
we generated HEK293 cells that expressed NLuc-b2-adreno-
ceptors under the control of the native promoter. These studies
showed a significant increase in the BRET ratio for NLuc-b2-
adrenoceptors expressed under the endogenous promoter
and exogenously transfected with 0.01 mg/well HaloTag-
VEGFR2 (fluorophore-labeled HaloTag-VEGFR2 compared
with cells where the HaloTag-VEGFR2 was not labeled with flu-
orophore) (Figures 4A and 4B). This supports the observation of
a specific VEGFR2-b2-adrenoceptor oligomeric complex and
Figure 3. Effect of Agonist Stimulation on
Receptor Oligomerization
(A) Schematic of experimental setup to investigate
the effect of isoprenaline or VEGF165a on receptor
oligomerization measured using NanoBRET.
(B) Visualization of VEGFR2/b2-adrenoceptor olig-
omers by NanoBRET using a luminescence LV200
Olympus microscope. HEK293 cells were tran-
siently co-transfected to express NLuc-tagged-
VEGFR2 and SNAP-tagged b2-adrenoceptors.
Sequential images were captured from unlabeled
(top panels) or SNAP-surface AF647-labeled co-
transfected cells (bottom panels). Sequential im-
ages were acquired by capturing DAPI channel,
displayed in the left panels (donor detection; using
a 438/24 nm emission filter, 5 s exposure time),
followed by CY5 channel, displayed in the right
panels (BRET-excited acceptor, using a 647 long-
pass filter, 30 s exposure time). Scale bar repre-
sents 20 mm.
(C and D) HEK293 cells were transiently trans-
fected with 0.05 mg/well NLuc-VEGFR2 and
0.10 mg/well SNAP-b2-AR and treated for 1 h at
37C with increasing concentrations of (C)
VEGF165aor (D) isoprenaline.BarCcorresponds to
untreated (control) condition. Data are means ±
SEM from five separate experiments, each
performed in quadruplicate. **p < 0.005 or
***p < 0.001 compared with control (C) (two-
way ANOVA with Dunnett’s multiple comparison
test).
(E and G) HEK293 cells were transiently trans-
fected with 0.05 mg/well NLuc-VEGFR2,
0.05 mg/well HaloTag VEGFR2 and 0.05 mg/well
SNAP-b2-AR (unlabeled) and treated for 1 h at
37C with increasing concentrations of VEGF165a
in the presence or absence of a fixed concentration
of isoprenaline (10 nM) (E) or increasing concen-
trations of isoprenaline alone (G). Data are means ±
SEM from five separate experiments each per-
formed in quadruplicate.
(F and H) HEK293 cells were transiently trans-
fected with 0.05 mg/well NLuc-b2-AR 0.05 mg/well
SNAP-b2-AR and 0.05 mg/well HaloTag VEGFR2
(unlabeled) and treated for 1 h at 37C with
increasing concentrations of (F) VEGF165a or (H)
isoprenaline. Data are means ± SEM from five or
six separate experiments each performed in
quadruplicate.also demonstrates that formation and detection of the com-
plexes is independent of tag orientation.
Electroporation of human umbilical vein endothelial cells
(HUVECs) = with NLuc-VEGFR2 also showed a significant in-
crease in BRET ratio (p < 0.05) when the cells were co-trans-
fected with SNAP-Tag-b2-adrenoceptor cDNA (Figure 4C) sug-
gesting that heterodimers can be formed in endothelial cells.
To investigate further the potential for endogenous VEGFR2
and b2-adrenoceptors to interact in HUVECs, we also investi-
gated their ability (alone and in combination) to stimulate cell pro-
liferation. As reported previously (Kilpatrick et al., 2017), 3 nM
VEGF165a was able to produce a large and significant enhance-
ment of cellular proliferation that could be inhibited by the tyro-
sine kinase inhibitor, cediranib (Figure S3). A very small but notsignificant increase in cell number was observed with both
high (10 mM) and low (100 nM) concentrations of isoprenaline
alone (Figure S3). However, in the presence of 10 mM isoprena-
line the response to 3 nM VEGF165a was significantly attenuated
(Figure S3).
We have previously reported that dimer formation can lead to
negative cooperativity between the ligand binding sites of the
two partners within an oligomeric complex (Gherbi et al., 2015;
May et al., 2011). Therefore, to investigate the potential for nega-
tive cooperativity across oligomeric interfaces, we took advan-
tage of our ability to measure ligand binding to NLuc-tagged
receptors using BRET and fluorescent ligands (Stoddart et al.,
2015; Kilpatrick et al., 2017). Clear saturable and high-affinity spe-
cific binding of the fluorescent ligand BODIPY CGP12177-TMRCell Chemical Biology 26, 830–841, June 20, 2019 833
Figure 4. HEK293 Cells Expressing Gene-Edited NLuc-b2-Adrenoceptor Labeled with HaloTag AF488 in the Absence or Presence of Tran-
siently Transfected HaloTag-VEGFR2 (0.01 mg/well)
(A) Data from a single experiment performed with 36 replicates. *p < 0.05 (unpaired t test) compared with donor alone. Similar data were obtained in four separate
experiments. In each repeat experiment significant differences (p < 0.05) were observed from donor alone apart from in one where p = 0.07.
(B) Mean paired data from the five separate experiments, each performed with 30 or 36 replicates. *p < 0.05 compared with donor only (paired two-tailed t test).
(C) Human umbilical vein endothelial cells (HUVECs) transiently transfected via electroporation with NLuc-VEGFR2 in the presence or absence of SNAP-b2-AR.
Data were pooled from eight independent transfections (four to eight replicates per experiment for each transfection) and expressed as mean ± SEM. *p < 0.05
compared with NLuc-VEGFR2 donor only (paired two-tailed t test; p = 0.035).to b2-adrenoceptors (KD = 67.2 ± 3.3 nM, n = 4; Figure S1C) was
observed, which was competitively antagonized by non-fluores-
cent b2-adrenoceptor ligands (Figure S1D). However, no signifi-
cant alteration in the binding of BODIPY CGP12177-TMR or
VEGF165a-TMR to their cognate receptors was observed with
the addition of ligands for the corresponding receptor heteromer
partner (Figure S4). Thus, VEGF165a did not influence the binding
of BODIPY CGP12177-TMR to the b2-adrenoceptor (Figure S4A)
and ICI118551, CGP12177, propranolol, and isoprenaline did not
influence binding of VEGF165a-TMR to VEGFR2 (Figure S4B).
Functional Impact of VEGFR2-b2-Adrenoceptor
Complexes on b2-Adrenoceptor Activation
To investigate the potential impact of VEGFR2 complexes on b2-
adrenoceptor signaling and function, we first studied whether
the VEGFR2-b2-adrenoceptor oligomeric complex altered the
extent to which an active b2-adrenoceptor could engage with a
conformation-sensitive single-domain nanobody (Nb80) that
has previously found use in structural studies as a Gs-alpha
surrogate protein (Rasmussen et al., 2011; Steyaert and Ko-
bilka, 2011). Here we used a GFP-tagged version of Nb80
(Irannejad et al., 2013) in conjunction with a b2-adrenoceptor
tagged on its C terminus with NLuc, to establish a NanoBRET
assay in living cells to monitor engagement (based on proximity)
between an activated b2-adrenoceptor and cytosolic Nb80-
GFP. Isoprenaline (10 mM) stimulation of stable Nb80-GFP-
expressing HEK293 cells, transiently transfected with b2-adre-
noceptor-NLuc, produced a rapid and significant binding of
Nb80-GFP to b2-adrenoceptors (Figure 5A; p < 0.001) confirming
the ability of Nb80-GFP to detect active conformations of the
b2-adrenoceptor. To investigate the impact of VEGFR2 on
b2-adrenoceptor signaling, we also transfected cells with either
HaloTag-VEGFR2 or an empty control vector. In cells addition-
ally transfected with the control empty vector, isoprenaline stim-
ulated the formation of a complex between the b2-adrenoceptor834 Cell Chemical Biology 26, 830–841, June 20, 2019and Nb80 (log EC50 = 7.91 ± 0.11, n = 6; Figure 5B). This
response was competitively antagonized by the high-affinity
b2-selective antagonist, ICI 118551 (log KD = 9.30 ± 0.20,
n = 6; Figure 5B). In the presence of VEGFR2, the response to
isoprenaline was unaltered, compared with control vector (Fig-
ure 5B). The successful expression of HaloTag-VEGFR2 in these
cells was confirmed at the end of the experiment by labeling cells
with the HaloTag substrate (data not shown).
Cellular Location of VEGFR2-b2-Adrenoceptor
Complexes
Confocal imaging of SNAP-tagged b2-adrenoceptors and Halo-
Tag-taggedVEGFR2 labeledwith cell-impermeable dyes showed
that, under basal conditions, cell surface b2-adrenoceptors
largely remained on the plasma membrane when expressed
alone (Figure S5A). However, as reported previously (Kilpatrick
et al., 2017), HEK293 cells expressing HaloTag-VEGFR2 showed
evidence of constitutive receptor internalization (Figure S5A).
Following treatment with 10 nM VEGF165a, VEGFR2 internaliza-
tion was markedly increased (Figure S5A). b2-adrenoceptor
internalization was also stimulated by isoprenaline (10 mM)
(Figure S5A). Following co-transfection of HEK293 cells with
HaloTag-VEGFR2 and SNAP-Tag b2-adrenoceptor cDNA, the
constitutive internalization of VEGFR2 appeared to be accompa-
nied by a low level constitutive internalization of the b2-adreno-
ceptor (Figure 6A). Isoprenaline (10 mM) stimulated a large
internalization of the b2-adrenoceptor that was co-localized with
internalized VEGFR2 (Figure 6A). Stimulation of co-transfected
cells with 10 nM VEGF165a produced an enhanced internalization
of VEGFR2 that was also accompanied by a partial internalization
of cell surface b2-adrenoceptors (Figure 6A). Co-localized
receptors were readily detected in intracellular Rab5-positive en-
dosomes under both basal or agonist-stimulated (VEGF165a or
isoprenaline) conditions (Figure 6B). Control experiments for
Rab5 localization are shown in Figure S5B.Structured illumination
Figure 5. Investigation of the Activation Sta-
tus of b2-AR Using Nb80-GFP
(A) HEK293 cells stably expressing Nb80-GFP were
transfected with 0.025 mg/well b2-AR-NLuc cDNA
and stimulated with isoprenaline (10 mM) or vehicle
control added at 5 min. A significant (p < 0.001) in-
crease in BRET ratio (relative to time zero) was
observed with isoprenaline from 8 min onward (two-
way ANOVA with repeated measures and Bonfer-
roni’s multiple comparison test). Data are means ±
SEM from five separate experiments each per-
formed in triplicate.
(B) HEK293 cells stably expressing Nb80-GFP were
transiently co-transfected with 0.025 mg/well b2-AR-
NLuc cDNA and either 0.025 mg/well empty vector
(pcDNA3.1) or 0.025 mg/well HaloTag-VEGFR2
cDNA. Cells co-transfected with empty vector were
treated with increasing concentrations of isoprena-
line, in the presence or absence of 100 nM ICI
118551, and cells co-transfected with HaloTag-
VEGFR2 were co-stimulated with 10 mM isoprena-
line and 10 nM VEGF165a. Bars correspond to
untreated and 100 nM ICI 118551-treated condi-
tions. Data are means ± SEM from six separate
experiments each performed in triplicate.super-resolution microscopy (SIM) confirmed that there was
co-localization of HaloTag VEGFR2 and SNAP-Tag b2-adreno-
ceptors at intracellular sites, which was elevated after agonist
stimulation (Figures 6C and 6D). The Fiji (ImageJ) analysis
program CoLoc2 was applied to these SIM images to determine
the extent of HaloTag VEGFR2 (green; HaloTag AF488 substrate)
and SNAP-Tag b2-adrenoceptor (red; SNAP-AF647 substrate)
fluorescence co-localization (Figure 6D). Circular regions of
interest (ROI) were placed on areas of fluorescence at the
plasmamembrane or intracellular regions (12–15 ROI; Figure 6E).
Pearson’s correlation coefficient values were obtained from
each ROI, pooled, and expressed as mean ± SEM. A Pearson’s
correlation coefficient of +1 is indicative of a perfect co-occur-
rence between the fluorophores of interest (AF488 and AF647,
respectively).
Interaction with b-Arrestin
Receptor internalization and signaling from endosomes are
regulated by b-arrestin scaffolding proteins (b-arrestin 1 and 2;
also known as arrestin2 and 3 [Shenoy and Lefkowitz, 2011;
Laporte et al., 2000; Luttrell et al., 2001; Eichel and von Zastrow,
2018]). Here we have used the Receptor Heteromer Investigation
Technology approach (Jaeger et al., 2014), with b-arrestin2-
Venus-YFP in combination with a b2-adrenoceptor tagged on
its C terminus with NLuc, to investigate using NanoBRET the
effect of VEGFR2 activation on isoprenaline-induced receptor
engagement with b-arrestin2 in cells co-expressing unlabeled
HaloTag-VEGFR2 (Figure 7A). Stimulation with 10 mM isoprena-
line alone induced b-arrestin2-Venus-YFP engagement with the
b2-adrenoceptor, which reached a peak between 4 and 6min af-
ter addition of the agonist (Figure 7B). Thereafter, the BRET
signal declined with time over the next 40 min (Figure 7). Howev-
er, when 10 nM VEGF165a was added at the same time as
isoprenaline, the activation of VEGFR2 altered the profile of the
b2-adrenoceptor engagement with b-arrestin2 (Figure 7B).
Thus, the peak response was slightly truncated and thereaftera plateau was rapidly achieved (9 min after agonist addition),
which was then maintained for the next 30 min (Figure 7B).
This plateau remained significantly higher (p < 0.05) than that
achieved with isoprenaline alone, where the response continued
to decline. This effect of VEGF165a was completely prevented by
pretreatment with the VEGFR2 RTK inhibitor cediranib (Fig-
ure 7B) (Carter et al., 2015). Studies of VEGFR2 phosphorylation
using a phospho-specific antibody for the tyrosine residue 1,212
did not provide evidence for enhanced phosphorylation of
VEGFR2 following stimulation with isoprenaline in cells co-
expressing b2-adrenoceptors (Figure S6). However, there was
a significant degree of constitutive VEGFR2 phosphorylation in
vehicle-treated cells (expressing both VEGFR2 and b2-adreno-
ceptors) that was inhibited by cediranib.
DISCUSSION
Here, we have demonstrated that VEGFR2 and a GPCR (the b2-
adrenoceptor) functionally interact in highly specific hetero-oligo-
meric complexes to modulate receptor localization, trafficking,
and downstream signaling. This was possible using NanoBRET
technology, which sensitively detects interactions between
protein-protein pairs (<10 nm apart). We found that the SNAP-
tagged-b2-adrenoceptor was in close proximity to NLuc-
VEGFR2, indicative of complex formation. Notably, stimulation
of either theGPCRorRTKwith a selective agonist (b2-adrenocep-
tor with isoprenaline or VEGFR2 receptor with VEGF165a) was
able to significantly enhance complex formation, as indicated
by an increased BRET signal. In contrast, we found no evidence
for interaction between the adenosine A3 receptor and VEGFR2.
This indicates that the RTK-GPCR heteromeric interactions
observed here are not simply a consequence of non-specific
bystander BRET, and that they are consistent with the docu-
mented physiological expression of b2-adrenoceptors and
VEGFR2, but not A3 receptors, on endothelial cells (Claesson-
Welsh and Welsh, 2013; Garg et al., 2017; Feoktistov et al.,Cell Chemical Biology 26, 830–841, June 20, 2019 835
Figure 6. Influence of Agonists on the
Cellular Location of Receptors and on Com-
plex Formation between b2-Adrenoceptors
and b-Arrestin2
(A) Confocal imaging (Zeiss LSM 710) of HEK293
cells transiently co-transfected with 0.25 mg/well
HaloTag- VEGFR2 and 0.25 mg/well SNAP-b2-AR
cDNAs, under unstimulated conditions (vehicle) or
after treatment with 10 mM isoprenaline or 10 nM
VEGF165a ligands (30 min at 37
C). Data are
representative of three individual experiments.
Scale bar represents 20 mm.
(B) Immunolabeling of early endosomes (anti-
Rab 5 antibody labeling). HEK293 cells tran-
siently co-transfected with 0.5 mg/well HaloTag-
VEGFR2 (green) and 0.5 mg/well SNAP-b2-AR
(red) cDNAs, under unstimulated conditions
(vehicle) or after treatment with 10 mM isopren-
aline or 10 nM VEGF165a (30 min at 37
C). Cells
were fixed using 3% paraformaldehyde/PBS,
permeabilized using Triton X-100 (0.025% in
PBS) and Rab 5 endosomal compartments
labeled (cyan). Cells were imaged using a
LSM880 confocal microscope (Zeiss). Data are
representative of three individual experiments.
Scale bar represents 10 mm.
(C) Structured illumination microscopy (SIM) su-
per-resolution images of HEK293 cells transiently
co-transfected with HaloTag-VEGFR2 (green) and
SNAP-b2-AR (red; 3 mg total cDNA). Cells were
incubated with vehicle, 10 mM isoprenaline or
10 nM VEGF165a (30 min at 37
C) before fixation
and mounting onto microscope slides. Coverslips
were imaged using a Zeiss ELYRA PS.1 micro-
scope. Areas of co-localized HaloTag-VEGFR2
and SNAP-b2-AR-labeled receptors are shown in
yellow. Scale bar represents 10 mm.
(D and E) Summary of Pearson’s correlation co-
efficients (D) obtained following co-localization
analysis of SIM images of circular regions of
interest (ROI) in HEK293 cells co-expressing
HaloTag-VEGFR2 and SNAP-b2-AR. ROI were
placed on areas of fluorescence either at the
plasma membrane or intracellular regions of SIM
images of HEK293 cells co-expressing HaloTag-
VEGFR2 (green; HaloTag AF488 membrane im-
permeant label) and SNAP-b2-AR (red; SNAP
AF647 membrane impermeant label). TetraSpeck
microspheres (0.1-mm spectral beads stained with
four fluorophores: 365/430 nm [blue], 505/515 nm
[green], 560/580 nm [orange], and 660/680 nm
[red]) were included in each experiment to allow X/Y/Z channel alignment correction in image processing. The Fiji (ImageJ) analysis program CoLoc2 was applied
to these ROI (six ROIs for spectral bead images and 12–15 ROIs for all other conditions) and Pearson’s correlation coefficients obtained. Values were averaged
across all ROI and are expressed as means ± SEM. A Pearson correlation coefficient value of +1 implies a perfect co-occurrence of both green (HaloTag-
VEGFR2) and red (SNAP-b2-AR) fluorophores. *p < 0.01 or **p < 0.001 compared with equivalent membrane condition. #p < 0.05 compared with equivalent
vehicle control. Examples of ROI are shown in (E).2002). RTK-GPCR hetero-oligomerization was also demon-
strated with genome-edited NLuc-b2-adrenoceptor expressed
under its endogenous promoter, where the extent of oligomeriza-
tion was limited to physiological levels by the availability of the
b2-adrenoceptor. The level of exogenously expressed HaloTag-
VEGFR2 that was available to interact with b2-adrenoceptor in
these cells was lower than endogenous levels of VEGFR2 in
HUVECs (Peach et al., 2018b), supporting the physiological rele-
vance of the observed hetero-oligomeric interactions.836 Cell Chemical Biology 26, 830–841, June 20, 2019These findings help to explain a striking feature of previous
work that investigated the membrane-diffusional properties of
receptor-ligand complexes in living cells using techniques such
as fluorescence correlation spectroscopy (FCS) (Briddon et al.,
2018). These studies suggested that the receptor species
diffusing in the cell membrane were much larger than expected
for a single membrane protein (or dimer) diffusing in isolation
(Briddon et al., 2018). This suggests that these receptors
may be normally present within macromolecular complexes of
Figure 7. Influence of b2-Adrenoceptor and
VEGFR2 Co-expression on b-Arrestin2
Recruitment
(A) Scheme showing the experimental setup for the
interaction between the b2-adrenoceptor-NLuc
(b2-AR-NLuc) and b-arrestin2 (bArr2).
(B) bArr2 recruitment time course performed with
HEK293 cells transiently co-transfected with
0.01 mg/well b2-AR-NLuc, 0.04 mg/well b-arrestin2-
Venus-YFP, and 0.04 mg/well HaloTag-VEGFR2. In
these experiments the HaloTag substrate was not
used and the HaloTag-VEGFR2 was used as an
untagged construct. Cells were challenged with
vehicle, 10 mM isoprenaline (Iso), or 10 mM
isoprenaline plus 10 nM VEGF165a (all added at
4 min), in the presence or absence of 1 mM cedir-
anib. *p < 0.05 between filled red and filled blue
data points from 26 min onward (two-way ANOVA with repeated measures and Bonferroni’s multiple comparison’s tests). Data are means ± SEM from five
(without cediranib treatment) or four (with cediranib treatment) separate experiments, each performed in triplicate wells.much higher molecular mass and/or have restricted lateral diffu-
sion. Since FCS has also identified multiple populations of
ligand-receptor complexes for both GPCRs and RTKs, this
suggests that multiple signaling complexes may exist in the
plasma membrane and elsewhere (Briddon et al., 2018; Thom-
sen et al., 2016). These observations are consistent with recent
work that has identified receptor-G protein interactions at cell
surface protein hotspots (Sungkaworn et al., 2017; Calebiro
and Sungkaworn, 2018) and also with work that has demon-
strated continued intracellular signaling from GPCRs in endo-
somes (Irannejad et al., 2013; Eichel and von Zastrow, 2018),
and the proposed importance of intracellular location to RTK
signaling (Weddell and Imoukhuede, 2017).
Our work has also demonstrated that VEGF165a-induced
VEGFR2 homodimerization still occurs in the presence of b2-
adrenoceptor expression, suggesting that the oligomeric com-
plexes detected by NanoBRET may be larger and contain
more than just the two specific partner proteins under study.
Thus, for example, VEGF165a may be enhancing the formation
of oligomeric complexes containing multiple copies of both
VEGFR2 and b2-adrenoceptors since it can enhance the forma-
tion of both VEGFR2-VEGFR2 and VEGFR2-b2-adrenoceptor
complexes (as determined by NanoBRET). In addition, b2-adre-
noceptors homodimers appear to be preformed since their for-
mation is not influenced by agonist (isoprenaline or VEGF165a)
stimulation.
The studies described here also provide evidence that recep-
tor oligomerization can modulate the localization and trafficking
of receptors. Confocal imaging studies in living cells expressing
an N-terminal SNAP-tagged b2-adrenoceptor and an N-termi-
nal-HaloTag variant of VEGFR2 showed that b2-adrenoceptors
largely remained on the plasma membrane under basal condi-
tions, whereas VEGFR2 (as observed by us previously [Kilpatrick
et al., 2017]) underwent constitutive internalization. When b2-
adrenoceptors and VEGFR2 were expressed together, there
was enhanced constitutive internalization of the b2-adrenocep-
tor and some co-localization with VEGFR2 at intracellular sites.
This was markedly enhanced following treatment with isoprena-
line and co-localized receptors were observed in Rab5-positive
intracellular endosomes. A similar situation occurred following
VEGF165a stimulation. Collectively these data suggest that,following agonist stimulation of one of the receptor partners,
there is enhanced co-localization (Figure 6) and oligomerization
(Figure 3) between VEGFR2 and b2-adrenoceptors within intra-
cellular endosomes.
The findings suggest that receptor hetero-oligomerizationmay
have evolved to expand the scope of downstream signaling that
occurs in response to receptor agonism. NanoBRET assays
demonstrated that the b2-adrenoceptor can regularly engage
with both a surrogate of the Gs-alpha subunit (Nb80) and with
b-arrestin2.
In the case of b-arrestin2, interaction of b2-adrenoceptors
occurred rapidly (within 4–6 min), with a gradual decline in
complex formation (indicated by reduced NanoBRET signal),
indicating dissociation of the receptor and signaling molecule.
While VEGFR2 stimulation with VEGF165a had no effect on the
absolute ability of the b2-adrenoceptor to engage with down-
stream signaling molecules, it was notable that simultaneous
stimulation of co-expressed b2-adrenoceptors and VEGFR2
altered the temporal characteristics of the interaction between
the b2-adrenoceptor and b-arrestin2. Thus, the maximal level
of b2-adrenoceptor/b-arrestin2 complex formation was trun-
cated, but the rate of complex dissociation was reduced, result-
ing in sustained complexes for the duration of the experiment
(>30 min). The requirement for VEGFR2 activation to alter b2-
adrenoceptor signaling dynamics was confirmed by blocking
the effect of VEGF165a by the VEGFR2 RTK inhibitor, cediranib
(Carter et al., 2015). Since activation of both VEGFR2 and b2-
adrenoceptor drive internalization of receptor complexes, it is
plausible that sustained b2-adrenoceptor/b-arrestin2 signaling
occurs in intracellular endosomes, which may have particular
implications for cellular proliferation and adds further complexity
to the spatial-temporal control of b2-adrenoceptor signaling
(Irannejad et al., 2013; Eichel and von Zastrow, 2018). These ob-
servations may be particularly relevant to the observed attenua-
tion of VEGF-induced cellular proliferation in HUVECswhen con-
centrations of b2-agonist are used that will stimulate the
recruitment of b-arrestin2 to the receptor (Figure 7). Thus, in
the presence of 10 mM isoprenaline, the effect of 3 nM VEGF165a
on cell proliferation is substantially reduced in human endothelial
cells (Figure S2) and this may be related to altered signaling from
intracellular endosomes. High concentrations of isoprenalineCell Chemical Biology 26, 830–841, June 20, 2019 837
(5–10 mM) have also been shown to enhance VEGF-dependent
angiogenic sprouting in HUVECs (Garg et al., 2017). Consistent
with this interaction between VEGFR2 and b2-adrenoceptors in
physiologically relevant human endothelial cells, we have also
obtained evidence for VEGFR2-b2-adrenoceptor oligomerization
(detected by BRET) in HUVECs.
The NanoBRET technology used in the current work repre-
sents a powerful proximity-based methodology to monitor pro-
tein-protein interactions involving different receptors in living
cells, as well as ligand binding to cell surface receptors. It reports
on the close proximity between two tagged partners that are
localized within 10 nm of each other (Stoddart et al., 2018).
The NanoBRET methodology also allowed us to investigate if
cooperativity occurred across interfaces of the oligomeric com-
plex of VEGFR2 with the b2-adrenoceptor, and demonstrated
that no such cooperativity occurs. We have previously shown,
using NanoBRET, that agonist-occupied receptor complexes
are rapidly internalized to intracellular endosomes (Kilpatrick
et al., 2017), and imaging studies in the current study suggest
that this is associated with internalization of VEGFR2-b2-adreno-
ceptor oligomeric complexes. Furthermore, NanoBRET studies
demonstrated that these receptor oligomers can associate
with, and alter signaling via, b-arrestin2.
In summary, we have demonstrated here that oligomeric
complexes involving VEGFR2 and b2-adrenoceptors can be
generated in cell membranes and intracellular endosomes
that retain their ability to couple to intracellular signaling path-
ways. Complexes involving the b2-adrenoceptor and VEGFR2
can co-internalize following agonist treatment. Furthermore,
VEGF165a or isoprenaline can stimulate further complex forma-
tion. VEGF165a treatment can also alter the temporal character-
istics of the isoprenaline-stimulated association between the
b2-adrenoceptor and b-arrestin2. These data suggest that
VEGFR2 and the b2-adrenoceptor may be key components of
membrane and endosomal macromolecular complexes, which
may have substantial implications for the spatiotemporal con-
trol of signaling driven by both of these receptors in physiolog-
ical or pathophysiological states. Furthermore the formation of
VEGFR2/b2-adrenoceptor complexes may provide insights
into their combined effects on endothelial cell proliferation
and the therapeutic benefit of the b2-adrenoceptor antago-
nist propranolol in the treatment of infantile hemangioma. In
addition, as both RTK and GPCR family members have been
implicated in driving cancer progression and metastasis, the
potential formation of distinct RTK/GPCR complexes may
represent anti-cancer therapeutic targets for drug discovery
efforts to exploit.
SIGNIFICANCE
The vascular endothelial growth factor receptor 2 (VEGFR2)
is a key mediator of angiogenesis and endothelial cell
proliferation following binding of its cognate ligand VEGF.
Therefore the VEGFR2/VEGF signaling axis is an attractive
therapeutic target in the treatment of conditions character-
ized by aberrant angiogenesis, such as cancer, and the com-
mon childhood tumor, infantile hemangioma. Interestingly
the b-adrenoceptor antagonist propranolol is the current
first-line treatment for infantile hemangioma; however, its838 Cell Chemical Biology 26, 830–841, June 20, 2019mechanism of action is not fully understood, although it is
believed to ultimately result in decreased VEGF expression
and cell proliferation. Activation of the b2-adrenoceptor has
also been suggested to augment VEGFR2 signaling in multi-
ple cancer types. We have used bioluminescence resonance
energy transfer (BRET) to demonstrate the existence of
oligomeric complexes between VEGFR2 and the b2-adreno-
ceptor at the plasma membrane and also within intracellular
compartments of living HEK293 cells and human umbilical
vein endothelial cells (HUVECs). The use of CRISPR/Cas9
gene editing in HEK293 cells illustrated that VEGFR2/
b2-adrenoceptor complexes were present, even when the
b2-adrenoceptor was expressed at endogenous levels.
These complexes can be induced by either VEGFR2 or b2-
adrenoceptor selective ligands, and are able to co-internalize
to shared intracellular compartments. These oligomeric
complexes can couple to intracellular signaling proteins,
and the presence of activated VEGFR2 is able to alter the
temporal profile of b-arrestin2 coupling to the b2-adrenocep-
tor in response to ligand stimulation. The existence of
VEGFR2/b2-adrenoceptor complexes may explain why the
b2-adrenoceptor-selective antagonist, propranolol, is thera-
peutically beneficial in the treatment of infantile hemangio-
ma. In addition the documented synergy of VEGFR2 and
b2-adrenoceptor signaling in many cancer types suggests
that the formation of complexes between these two recep-
tors subtypes could represent anti-cancer therapeutic
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STAR+METHODSKEY RESOURCES TABLEREAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Anti Rab5 antibody (rabbit monoclonal; primary) New England Biolabs (Cell Signaling
Technology)
Cat# 3547; RRID: AB_2300649
Donkey anti rabbit IgG Alexa Fluor 568 (secondary) ThermoFisher Scientific, USA Cat# A10042; RRID: AB_2534017
Rabbit monoclonal anti-VEGFR2 phosphoY1212 Cell Signalling Cat# 2477; RRID: AB_331374
Chicken anti rabbit AF488 conjugated secondary antibody Thermo Fisher Scientfic, USA Cat# A21441; RRID: AB_141735
Chemicals, Peptides, and Recombinant Proteins
VEGF165a R&D Systems (Abingdon, UK) Cat# 293-VE
VEGF165a-TMR Promega Corporation (Wisconsin, USA) Custom synthesis
HaloTag AlexaFluor 488 membrane impermeant substrate Promega Corporation (Wisconsin, USA) Cat# G1002
HaloTag AlexaFluor 660 membrane impermeant substrate Promega Corporation (Wisconsin, USA) Cat# G8471
SNAPTag AlexaFluor 488 membrane impermeant substrate New England Biolabs Cat# S9124S
SNAPTag AlexaFluor 647 membrane impermeant substrate New England Biolabs Cat# S9136S
Formaldehyde solution 4% Sigma Aldrich Cat# F8775
Cediranib Sequoia Research Products Cat# SRP01883c
Protease-free bovine serum albumin Sigma Aldrich Cat# 03117332001
ProLong Glass antifade reagent ThermoFisher Scientific, USA Cat# P36965
Dulbecco’s Modified Eagle’s Medium Sigma Aldrich Cat# D6429
CitiFluor mounting medium CitiFluor, USA Cat# E17979-20
Medium 200 ThermoFisher Scientific, USA Cat# M200500
LVES 50x (large vessel endothelial cell supplement) ThermoFisher Scientific, USA Cat# A14608-01
ImmersolTM 518F (30C) oil Zeiss, Germany Cat# 444970-9000-000
Ingenio electroporation kit Mirus Bio Cat# MIR50114
Fetal Bovine Serum Sigma Aldrich Cat# F2442
Propranolol hydrochloride Tocris Cat# 0624
Isoproterenol (isoprenaline) hydrochloride Sigma Aldrich Cat# I6504
ICI 118551 hydrochloride Tocris Cat# 0821
CGP12177 hydrochloride Tocris Cat# 1134
CGP12177-TMR Molecular Probes, Oregon, USA Described in Baker et al., 2003
Opti-MEM reduced serum medium ThermoFisher Scientific Cat# 11058021
Poly-D-Lysine hydrobromide
Dulbecco’s
Sigma Aldrich Cat# P6407
Dulbecco’s Phosphate Buffered Saline (DPBS) Sigma Aldrich Cat# D8537
Trypsin-EDTA solution x10 Sigma Aldrich Cat# T4174
Chicken serum Sigma Aldrich Cat# C5405
Puromycin dihydrochloride from Streptomyces alboniger Sigma Aldrich Cat# P8833
FuGENE HD Promega Cat# E2311
Triton-X-100 Sigma Aldrich Cat# X100
Glycine Sigman Aldrich Cat# G8898
bisBenzimide H33342 trihydrochloride Sigma Aldrich Cat# B2261
Critical Commercial Assays
ONE-GloTM Luciferase Promega Corporation (Wisconsin, USA) Cat# E6120
Nano-Glo luciferase assay system (Furimazine) Promega Corporation (Wisconsin,USA) Cat# N1130
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Experimental Models: Cell Lines
Human: GloResponseTM NFAT-RE-luc2P HEK293 cell line
(female)
Promega Corporation (Wisconsin, USA) Cat# E8510
Human: HEK293T cells (female) ATCC (Virginia, USA) Cat# CRL-3216
Human: HUVEC cells (newborn male, single donor) ThermoFisher Scientific Cat# C0035C. Lot number:
1606186.
Recombinant DNA
NanoLuc-VEGFR2 Promega Corporation (Wisconsin, USA) Custom synthesis
HaloTag-VEGFR2 Promega Corporation (Wisconsin, USA) Custom synthesis
NanoLuc-b2AR Promega Corporation (Wisconsin, USA) Custom synthesis
NanoLuc-A3R Stoddart et al., 2015 Custom synthesis
SnapTag-b2AR Gherbi et al., 2015 Custom synthesis
SnapTag- A3R Stoddart et al., 2014 Custom synthesis
pSIN-Nb-80-GFP Described in this manuscript. Custom synthesis
b2AR-NanoLuc Promega Corporation (Wisconsin, USA) Custom synthesis
b-arrestin2-Venus-YFP Kocan et al., 2008 Custom synthesis
pSpCas9(BB)-2A-Puro (PX459) V2.0 Addgene Plasmid #62988;
RRID: Addgene_62988
ADRB2 Homology directed repair template GeneArt (Thermofisher Scientific) Custom synthesis
Oligonucleotides Sigma Aldrich Custom synthesis
Software and Algorithms
GraphPad Prism 7.02 GraphPad Software, La Jolla California USA https://www.graphpad.com/
scientific-software/prism/
Zen 2010 Zeiss, Germany www.zeiss.com
ImageJ Fiji 1.52e (Coloc2 plug in) National Institute of Health, USA https:/fiji.sc
Other
White 96-well plates Greiner Bio-One Cat# 655089
Black 96-well plates Greiner Bio-One Cat# 655090
Nunc Lab-Tek 8-well chambered coverslips ThermoFisher Scientific Cat# 1554411
Coverslips (18x18mm; 1.5H) Zeiss, Germany Cat# 474030-9000-000
4-chamber 35mm dish with 20mm bottom well containing
1.5mm glass coverslip
Cellvis, California, USA Cat# D35C4-20-1.5-N
BbsI restriction enzyme New England Biolabs (UK) Cat# R0539S
BamH1 restriction enzyme Promega Corporation (Wisconsin, USA) Cat# R6021
BglII restriction enzyme Promega Corporation (Wisconsin, USA) Cat# R6081
XhoI restriction enzyme Promega Corporation (Wisconsin, USA) Cat# R6161
XbaI restriction enzyme Promega Corporation (Wisconsin, USA) Cat# R6181
KpnI restriction enzyme Promega Corporation (Wisconsin, USA) Cat# R6341
SpeI restriction enzyme Promega Corporation (Wisconsin, USA) Cat# R6591
T4 DNA ligase Promega Corporation (Wisconsin, USA) Cat# M1801
Gibson Assemby Master mix New England Biolabs (UK) Cat# E26115
Pfu DNA polymerase Promega Corporation (Wisconsin, USA) Cat# 7741
TetraSpeckTM microspheres (0.1mm) Thermo Fisher Scientific Cat# T7279CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Stephen
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Human HEK293T cells (female) were obtained from ATCC (Virginia, USA) and the human GloResponseTM NFAT-RE-luc2P HEK293
cell line (female) was obtained from Promega Corporation (Wisconsin, USA). Human umbilical endothelial (HUVEC) cells (newborn
male, single donor) were obtained from Thermo Fisher Scientific (Waltham, USA). HUVECs and HEK293T cells were transfected
and cultured as described in Method Details.
METHOD DETAILS
Materials
All materials were purchased from Sigma-Aldrich (Gillingham, UK) unless otherwise stated. FuGENE-HD, ONE-Glo luciferase
and HaloTag AF488 ligand were purchased from Promega Corporation (Wisconsin, USA). Opti-MEM was purchased from
Thermo-Fisher Scientific (Massachusetts, USA). SNAP-Tag AlexaFluor 647 (AF647) and AlexaFluor 488 (AF488) were purchased
from New England BioLabs (Massachusetts, USA). VEGF165a was purchased from R&D Systems (Abingdon, UK). VEGF165a-TMR
was produced as described by Kilpatrick et al. (2017). BODIPY-CGP12177-TMR (Baker et al., 2003) was purchased from Molecular
Probes (Oregon, USA). CGP12177 and ICI118551 were purchased from Tocris Bioscience (Bristol, UK). The cDNA construct
expressing b-arrestin2-Venus-YFP was provided by Dr KDG Pfleger and generated as described in Kocan et al. (2008).
Molecular Biology
NLuc- and HaloTag-VEGFR Constructs
NLuc-VEGFR2 and HaloTag-VEGFR2 constructs were generated as described in Kilpatrick et al., 2017). Briefly, VEGFR2 was subcl-
oned from a plasmid obtained fromOrigene (GenBank: NM_002253; Maryland, USA). VEGFR2 was cloned into a pF-sNnK CMV/neo
vector (N1321; Promega Corporation, USA) encoding a fusion of the signal peptide sequence of IL-6 onto the N terminus of NanoLuc
(NLuc). This resulted in open reading frames (ORFs) which encoded NLuc fused via a Gly-Ser-Ser-Gly(AIA) linker to the N terminus of
VEGFR2 (termed NLuc-VEGFR2). For the N terminal HaloTag construct, VEGFR2 cDNA was cloned into a pFN21A CMV/neo flexi
vector encoding a fusion of the signal peptide sequence of IL-6 onto theN terminus of HaloTag. The resultant ORFs encodedHaloTag
fused to the N terminus of VEGFR2 via a EPTTEDLYFQSDN(AIA) linker (HaloTag VEGFR2).
NLuc- and SNAP-Tag- Adenosine A3-Receptor Constructs
The generation of NLuc-A3-receptor (Stoddart et al., 2015) and SNAP-A3-receptor (Stoddart et al., 2014) pcDNA3.1 plasmids has
been described previously. We generated NLuc-labeled adenosine receptor constructs by amplifying the full length sequence of
NLuc luciferase (as provided by PromegaCorporation in the pNL1.1 vector) and fusing it in framewith themembrane signal sequence
of the 5HT3A receptor within pcDNA3.1(+) to yield sig-NLuc. We then fused the full-length human sequence of the adenosine A3-re-
ceptor (obtained from Missouri S&T cDNA Resource Centre; www.cdna.org; GenBank: AY136749) with the methionine start signal
removed, to the 30 end of the sig-NLuc in pcDNA3.1(+). This gave the construct designated as NLuc-A3 receptor. To generate N-ter-
minal SNAP-tagged adenosine A3 receptor, the methionine start signal was removed from cDNA encoding the full length A3-receptor
and subcloned into a pcDNA3.1-zeo (+) vector containing the 5HT3-receptor-derived signal sequence followed by the SNAP Tag
sequence (New England Biolabs, Ipswich, MA, USA).
b2-Adrenoceptor Constructs
Theb2-adrenoceptor cDNAsequence (obtained fromMissouri S&TcDNAResourceCentre;www.cdna.org;GenBank:NM_000024.3)
was PCR amplified to generate a b2-adrenoceptor sequence that was in frame with the BamHI restriction site of sig-NLuc (Stoddart
et al., 2015) and sig-SNAP (Gherbi et al., 2015), and changed the start codon (Met) of the b2-adrenoceptor sequence to Leu. The
primers used were forward 5’-CCGCCGGATCCCTGGGGCAACCCGGGAACG-3’ and reverse 5’-GGCGGGAATTCTTACAGCAGT
GAGTCATTTG-3’. The PCR product was then ligated in frame into pcDNA3.1(+) containing sig.SNAP (Gherbi et al., 2015) or sig-
NLuc (Stoddart et al., 2015) using BamHI and EcoRI restriction enzymes. This created the plasmids sig-SNAP-ADRB2-pcDNA3.1(+)
and sig-NLuc-ADRB2-pcDNA3.1(+). b2-NLuc adrenoceptor in the pF-sNnK vector was obtained from Promega Corporation.
Nb80-GFP
The synthesis of Nb80 encoding cDNA was based on the amino acid sequence information published previously (Rasmussen et al.,
2011). This sequence was first reverse translated into nucleotide sequence and then codon optimised for expression in human cells.
The designed fragment was assembled via the Gibson reaction (Gibson et al., 2009) according to manufacture protocol (Gibson
Assembly master mix, E2611S NEB) with the following set of overlapping primers:
Nb80Fwd1:5’ATGGGACAGGTGCAGCTGCAGGAGAGCGGCGGCGGCCTGGTGCAGGCCGGCGGCAGCCTGAGACTGAGC
TGCGCCGCCAGCGGCAGCATCTTCAGCATCAACACCATGGG-3’; Nb80Rev2:5’TGCCCTTCACGCTGTTGGCGTAGTTGGTG
CTGCCGCCGCTGTGGATGGCGGCCACCAGCTCTCTCTGCTTGCCGGGGGCCTGTCTGTACCAGCCCATGGTGTTGATGCTG-3’;
Nb80Fwd3:5’CGCCAACAGCGTGAAGGGCAGATTCACCATCAGCAGAGACAACGCCGCCAACACCGTGTACCTGCAGATGAACAG
CCTGAAGCCCGAGGACACCGCCGTGTACTACTGCA-3’; Nb80Rev4:5’GTGGTGGTGGTGGTGGTGGCTGCTCACGGTCACCTGG
GTGCCCTGGCCCCAGTAGTCGTACTCGTACAGCACGGCGCCGTAGTCCTTCACGTTGCAGTAGTACACGGCGG-3’.e3 Cell Chemical Biology 26, 830–841.e1–e9, June 20, 2019
TheGibson reaction product was further PCR amplified with Nb80Fwd5 5’-CTTCGAACTAGTGCCGCCACCATGGGACAGGTGCA
GCTGCAG-3’ & Nb80Rev6 5’- GGTGGCACTAGTGACCGGTATGTGGTGGTGGTGGTGGTGGCTGCTC primers, digested with SpeI
restriction enzyme and cloned in to SpeI linearized pSIN-eGFP-BSD plasmid (Dixon et al., 2011) resulting in the pSIN-Nb80-GFP
expression vector.
CRISPR/Cas9 Guide and Donor Vector Cloning
Guide RNA construction was performed as described previously in the detailed protocol (Ran et al., 2013). Briefly, two guide
sequences, sgRNA1: CCTGCCAGACTGCGCGCCAT and sgRNA2: TTGCCCCATGGCGCGCAGTC targeting the N-terminal region
of ADRB2were designed using the CRISPR Design Tool (Hsu et al., 2013) (http://crispr.mit.edu/) and were ligated as complementary
oligonucleotides into the pSpCas9(BB)-2A-Puro (PX459) expression construct (from Feng Zhang, Addgene plasmid # 62988)
linearized by the restriction enzyme BbsI.
Primers used for sgRNA1 construction were:
forward 5’-CACCGCCTGCCAGACTGCGCGCCAT-3’ and
reverse 5’-AAACATGGCGCGCAGTCTGGCAGG-3’
and for sgRNA2 were:
forward 5’-CACCGTTGCCCCATGGCGCGCAGTC-3’ and
reverse 5’- AACGACTGCGCGCCATGGGGCAA-3’.
To introduce DNA encoding NLuc into the ADRB2 locus a donor repair template was designed using the UCSC genome browser
(http://genome.ucsc.edu/, Human genome assembly (GRCh38/hg38) (Kent et al., 2002). Homology arms, left (hg38 chr5:148826832-
148826057) and right (hg38 chr5: 148826836-148827611), surrounding but not including theADRB2 start codonwere synthesized as
double stranded DNA by GeneArt (Invitrogen). A short linker was included between the homology arms to allow ligation of sig-NLuc
(Stoddart et al., 2015) into the template using the restriction enzymes KpnI and BamHI. A mutation introduced during synthesis to
remove an internal KpnI restriction site was then corrected by site-directed mutagenesis. The primers used were forward 5’-CAG
ATGCACTGGTACCGGGCCACC-3’ and reverse 5’- GGTGGCCCGGTACCAGTGCATCTG-3’. The donor template therefore resulted
in cells expressing gene-edited sig-Nluc-b2-adrenoceptor with the start codon (Met) of the b2-adrenoceptor deleted.
Heterozygous in-frame insertion of NLuc into the ADRB2 locus was observed by PCR of purified genomic DNA and verified by
Sanger sequencing of overlapping PCR amplicons.
Primer sets used for PCR and sequencing were:
Amplicon 1, forward 5’-TTCGGAGTACCCAGATGGAG-3’ and
reverse 5’- GTCTTGAGGGCTTTGTGCTC-3’.
Amplicon 2, forward 5’-TTCGGAGTACCCAGATGGAG-3’ and
reverse 5’-ACAGGCCAGTGAAGTGATGA-3’.
Amplicon 3, forward 5’-GACAAGCTGAGTGTGCAGGA-3’ and
reverse 5’- GTCTTGAGGGCTTTGTGCTC-3’
Primers in italics anneal outside of the donor repair template.
Cell Culture
All HEK293 cell lines used here were HEK293T cells grown in Dulbecco’s Modified Eagle’s Medium (DMEM6429) supplemented with
10% fetal calf serumat 37C/5%CO2. All stable and transient transfections were performed using FuGENEHDaccording to theman-
ufacturer’s instructions. TheNLuc-b2-adrenoceptor stable HEK293 cell line was provided by PromegaCorporation (Wisconsin, USA).
Cell passaging was performed when cells reached 80% confluency using PBS (Lonza, Switzerland) and trypsin (0.25% w/v in
versene; Lonza, Switzerland).
CRISPR/Cas9 genome-engineering of HEK293 cells was performed as described previously (White et al., 2017). Briefly, HEK293
cells were seeded into 6 well plates and incubated for 24h at 37C/5% CO2. At 60% confluency, cells were transfected with px459
sgRNA/Cas9 expression constructs and the donor repair template. Cells were cultured for 24h then treated with puromycin
(0.3ug/ml) for 3 days to select for transfected cells. Following selection, cells were cultured without puromycin for 1 day then seeded
into clear flat bottom 96-well plates at 1 cell per well and allowed to expand for 2-3 weeks. Single colonies were screened for
luminescence following the addition of furimazine (10mM) using a PHERAStar FS plate reader. Positive clones were expanded before
cells were collected for genotyping and sequencing.
Human umblical vein endothelial cells (HUVECs; passage 2-8) were grown inMedium 200 (ThermoFisher, USA) supplemented with
LVES 50x large vessel endothelial cell supplement (ThermoFisher, USA) at 37C/5% CO2. Cell passaging was performed when cells
reached 70% confluency using PBS (Lonza, Switzerland) and trypsin (0.25% w/v in versene; Lonza, Switzerland).
NanoBRET Assays to Determine Fluorescent Ligand Saturation Binding
HEK293 cells stably expressing full length cDNA encoding an N-terminal NLuc-tagged b2-adrenoceptor (Stoddart et al., 2015) or
NLuc-VEGFR2 (Kilpatrick et al., 2017) were seeded into poly-D-lysine coated white flat bottom 96 well plates (655089; Greiner
Bio-One, Stonehouse, UK), and incubated for 24h at 37C/5%CO2. On the day of the assay, cells were washed and incubated
with 1x HEPES Buffered Salt Solution (HBSS; 10mM HEPES, 10mM glucose, 146mM NaCl, 5mM KCl, 1mM MgSO4, 2mM sodium
pyruvate, 1.3mM CaCl2; pH 7.2), pre-heated at 37
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fluorescent ligand for b2-adrenoceptor or VEGFR2 (BODIPY-CGP12177-TMR or VEGF165a-TMR respectively) in HBSS for 60min at
37C. Non-specific binding was defined using unlabelled subtype selective ligands (10mM propranolol or 10nM VEGF165a respec-
tively). All VEGF incubations were performed using HBSS supplemented with 0.1% BSA. Following ligand incubation, 10mM of
the NLuc substrate furimazine was added in the dark and plates left for 5min at room temperature. Sequential emission measure-
ments were taken using a PHERAStar FS plate reader using 460nm (80nm bandpass; donor NLuc emission) and 610nm (longpass
filter; fluorescent ligand emission) filters. Raw BRET ratios were calculated by dividing the 610nm emission (acceptor) by the 460nm
emission (donor).
NanoBRET Saturation Assays to Investigate Receptor-Receptor Interactions
For homodimer studies, HEK293 cells were seeded into poly-D-lysine coatedwhite flat bottom 96well plates and incubated for 24h at
37C/5% CO2. At 70% confluency, cells were transiently transfected with a fixed concentration of N-terminal NLuc-tagged donor
receptor constructs (0.05mg/well VEGFR2; 0.05mg/well b2-adrenoceptor or A3-receptor respectively) and increasing concentrations
of N-terminal-tagged acceptor constructs (0.025-0.2mg/well HaloTag- VEGFR2; or 0.025-0.2mg/well SNAP Tag-b2-adrenoceptor or
A3-receptor). When investigating the effect of ligand stimulation on the formation of VEGFR2 homodimers, a 1:1 (0.05:0.05mg/well)
ratio of donor (NLuc-VEGFR2) to acceptor (HaloTag-VEGFR2) was also prepared. All transfections were performed using FuGENE
HD in Opti-MEM according to themanufacturer’s instructions. Empty p3.1zeo vector was usedwhen necessary to ensure total cDNA
concentrations were kept consistent across all wells. Cells were left to grow for a further 24h at 37C/5% CO2.
On the day of the assay, 24h post transfection, cells were incubated for 30min at 37C/5%CO2 with 0.2mM HaloTag AF488 or
0.2mM SNAP-Tag AF488 membrane impermeable substrate, prepared in serum-free DMEM. After incubation, cells were washed
3 timeswith HBSS pre-heated to 37C. VEGFR2 homodimers, were stimulatedwith vehicle or 1nMVEGF165a in HBSS supplemented
with 0.1% BSA for 60min at 37C. All other BRET homodimer pairs were incubated in vehicle (HBSS) for 60min at 37C. When inves-
tigating whether VEGFR2 dimer formation was ligand dependent, NLuc-VEGFR2:HaloTag-VEGFR2 homodimers (0.05mg/well
HaloTag-VEGFR2 transiently transfected into NLuc-VEGFR2 stable cell line) were stimulated with a concentration response course
of VEGF165a (0.25-10nM) for 60min at 37
C. 10mM of the NLuc substrate furimazine was then added to each well and plates left for
5min in the dark at room temperature. Sequential emission measurements were taken using a PHERAStar FS plate reader using
460nm (80nm bandpass; donor NLuc emission) and 535nm (60nm bandpass; HaloTag or SNAP-Tag emission) filters. Raw BRET
ratios were calculated by dividing the 535nm emission (acceptor) by the 460nm emission (donor).
For heterodimer studies, HEK293 cells were seeded into poly-D-lysine coated white flat bottom 96 well plates and incubated for
24h at 37C/5%CO2. At 70% confluency, cells were transiently transfected with a fixed concentration of donor N-terminal tagged
NLuc-VEGFR2 (0.05mg/well) and increasing concentrations of N-terminal-tagged acceptor receptor constructs (0.002-0.04mg/well
or 0.025-0.2mg/well for SNAP-Tag-b2-adrenoceptor or A3-receptor respectively). All transfections were performed using FuGENE
HD in Opti-MEM according to the manufacturer’s instructions. Empty p3.1zeo vector was used when necessary to ensure total
cDNA concentrations were kept consistent across all wells. Cells were left to grow for a further 24h at 37C/5%CO2. On the day
of the assay, 24h post transfection, cells were incubated for 30min at 37C/5%CO2 with 0.2mM HaloTag AF488 or 0.2mM SNAP-
Tag AF488 membrane impermeable substrate, prepared in DMEM/10% FCS. After incubation, cells were washed 3 times with
HBSS pre-heated to 37C. VEGFR2/combinations were stimulated with vehicle or 3nM VEGF165a in HBSS/0.1% BSA for 60min
at 37C. For all other BRET combinations, cells were incubated in vehicle (HBSS) for 60min at 37C. Following this, 10mM of the
NLuc substrate furimazine was added to each well and plates left for 5min in the dark at room temperature. Sequential luminescent
and fluorescent emission measurements were recorded using a PHERAStar FS plate reader as previously described for homodimer
studies.
For studies using CRISPR/Cas9 edited cells, HEK293 expressing gene-edited Nluc-b2-adrenoceptors were seeded into poly-D-
lysine coated white flat bottom 96 well plates at a density of 15,000-20,000 cells/well and incubated for 24h at 37C/5%CO2. Cells
were then transiently transfected with Halotag-VEGFR2 (0.01mg/well) plus empty p3.1zeo vector (0.09mg/well). Cells were left to grow
for a further 24h at 37C/5%CO2. On the day of the assay, 24h post transfection, cells were incubated for 30min at 37C/5%CO2 with
0.2mMHaloTag AF488 prepared in DMEM/10% FCS. After incubation, cells were washed 3 times with HBSS pre-heated to 37C and
further incubated in vehicle (HBSS) for 60min at 37C. Following this, 10mMof the NLuc substrate furimazine was added to each well
and plates left for 5min in the dark at room temperature. Sequential luminescent and fluorescent emission measurements were
recorded using a PHERAStar FS plate reader as previously described for homodimer studies.
For studies using HUVECs (passage 2-8), cells were passaged, counted and resuspended at 350,000 cells in Ingenio electropo-
ration solution (100ml; Ingenio electroporation kit; Mirus Bio, Wisconsin, USA). The appropriate cDNA was added to this cell
suspension (NLuc-VEGFR2/pcDNA3.1 zeo cDNA (2mg cDNA respectively per 0.1ml cell suspension) or NLuc-VEGFR2/ SNAP
Tag-b2-adrenoceptor (2mg cDNA respectively per 0.1ml cell suspension). HUVECs were then electroporated at room temperature
using an Amaxa Nucleofector I (programme V-001) and immediately resuspended in Medium 200, plated onto white flat bottomed
Grenier 96 well plates (Greiner Bio-One, 655089) and left to grow for 24h at 37C/5%CO2. On the day of the assay, HUVECs were
incubated for 30min at 37C/5%CO2 with 0.2mM SNAP-Tag AF488 prepared in DMEM/10% FCS. After incubation, cells were
washed 3 times with HBSS pre-heated to 37C, 10mM of the NLuc substrate furimazine was added to each well and plates left
for 5min in the dark at room temperature. Sequential luminescent and fluorescent emission measurements were recorded using a
PHERAStar FS plate reader as previously described for homodimer studies (3600/3600 gain values) using a focal height of 4.2mm.e5 Cell Chemical Biology 26, 830–841.e1–e9, June 20, 2019
Widefield Bioluminescence Microscopy
Bioluminescence imaging was performed using an Olympus LV200 Wide field inverted microscope, equipped with a 60x/1.42NA oil
immersion objective lens. HEK293 cells at a density of 70,000 cells/well were seeded into a 35mm MatTek dish split in 4-wells,
containing a high tolerance 1.5mm coverslip. 24h later, cells were co-transfected with NanoLuc-tagged human VEGFR2 and
SNAP-tagged human b2-adrenoceptor cDNAs (0.4mg each). Before imaging, media was removed, and cells were incubated with
either serum-free DMEM or 0.5mM SNAP-surface AF647 substrate and incubated for 30min at 37C/5%CO2. After incubation,
cells were washed three times and incubated with HBSS containing 400nM furimazine substrate (Promega) at 37C for 15min.
Images were acquired by capturing sequential channels: 1) TRITC channel using an external LED lamp excitation (acceptor
excitation; using 561/14nm excitation and a 647 long-pass emission filters, 200ms exposure time) ; 2) DAPI channel (donor
emission; using a 438/24nm emission filter, 5sec exposure time); 3) CY5 channel (BRET-excited acceptor; using a 647 long-pass
emission filter, 30sec exposure time). All images were acquired with gain set to 200. Images were exported using Fiji ImageJ version
1.52e software.
NanoBRET Assays to Investigate the Effects of Isoprenaline or VEGF165a on Heteromer Formation
HEK293 cells were transiently transfected with a 1:2 cDNA ratio (0.05:0.1mg/well) of donor (NLuc-VEGFR2) to acceptor (SNAP Tag-
b2-adrenoceptor) constructs using FuGENEHD inOpti-MEMat a reagent to cDNA ratio of 3:1. Cells were then left to grow for a further
24h at 37C/5%CO2. On the day of the assay cells were incubated with 0.2mMSNAP-Tag AF488membrane impermeable substrate,
prepared in DMEM (30min at 37C). Cells were then washed 3 times with HBSS and stimulated with fixed concentrations of isopren-
aline or VEGF165a for 60min at 37
C. VEGF165a stimulations were performed in HBSS/0.1% BSA for 60min at 37C. At the end of the
assay course, 10mMof furimazine was added per well and plates read using a PHERAStar FS as previously described for homodimer
studies.
NanoBRET Assays to Investigate Potential for Cooperativity across Putative Receptor Dimer Interfaces
HEK293 cells were transiently transfected with a 1:2 cDNA ratio (0.05:0.1mg/well) of donor (NLuc-VEGFR2 or NLuc-b2-adrenoceptor)
to acceptor (SNAP-Tag-b2-adrenoceptor or HaloTag-VEGFR2) constructs using FuGENEHD in Opti-MEM at a reagent to cDNA ratio
of 3:1. Cells were then left to grow for a further 24h at 37C/5%CO2. On the day of the assay, cells were co-stimulated with a fixed
concentration of fluorescent ligand (VEGF165a-TMR (1 or 2nM) or BODIPY CGP12177-TMR (15nM)) in the presence or absence of
increasing concentrations of unlabeled subtype selective ligands (ICI,118551 (0.01nM-10mM); CGP12177 (0.01nM-10mM) or isopren-
aline (0.1nM-100mM)). Nonspecific binding of fluorescent ligands was defined using a high concentration of unlabeled ligands (10nM
VEGF165a or 10mM propranolol). All ligand co-incubations were performed in HBSS for 60min at 37
C. 10mM of the NLuc substrate
furimazine was added to each well and plates left for 5min in the dark at room temperature. Sequential emission measurements were
taken using a PHERAStar FS plate reader using 460nm (80nm bandpass; donor NLuc emission) and 610nm (longpass filter; fluores-
cent ligand emission) filters. Raw BRET ratios were calculated by dividing 610m emission (acceptor) by 460nm emission (donor).
VEGFR2 Phosphorylation Assay
HEK293T cells were seeded at 15,000 cells/well in black flat-bottomed 96-well plates (Greiner Bio-One, 655090) pre-coated with
poly-D-lysine (0.01mg/ml in PBS). Following 24 h, cells were transfected with HaloTag-VEGFR2 in the presence or absence of Snap-
Tag-b2-adrenoceptor (0.05mg/well of each) using FuGENE HD in serum free DMEM at a reagent to cDNA ratio of 3:1. Cells were then
grown for another 24 hours (37C/5% CO2). On the day of the assay, cells were labeled using membrane impermeant SNAP-Tag
AF647 substrate (0.2mM; 30min at 37C) prepared in DMEM (30min at 37C). Cells were then washed 3 times with HBSS and stim-
ulated for 15 or 60min with 3nMVEGF165a, 100nM isoprenaline or both ligands simultaneously. The receptor tyrosine kinase inhibitor
cediranib (1mM; Sequoia Research Products, UK) was used a negative control. Cells were washedwith 100ml/well PBS, fixedwith 3%
paraformaldehyde (PFA)/PBS for 20min at room temperature), washed (3x5min PBS), permeabilised with 0.025% Triton-X-100 in
PBS, washed (3x5min PBS) and incubated with 3%BSA/1% glycine/PBS to reduce non-specific binding (30min, room temperature).
After washing (3x5min PBS), cells were blocked with 10% chick serum in PBS (30min, room temperature) and incubated at 4C over-
night with rabbit monoclonal anti-VEGFR2 phosphoY1212 (Cell Signalling, 2477) diluted 1:200 in 10% chick serum/PBS. Cells were
washed (3x5min PBS) and incubated in the dark at room temperature with secondary antibody chick anti-rabbit AlexaFluor488
(Thermo Fisher, A21441). Nuclei were stained with 2mg/ml H33342 (15min, room temperature), washed and stored at 4C in PBS.
Cells were imaged using an ImageXpressMicro widefield high content imaging system (Molecular Devices, USA) with a 20x objective
at 4 sites per well using FITC, DAPI and CY5 filters (exposure 25ms, 1500ms and 1500ms respectively).
HUVEC Proliferation Assay
HUVECs (passage 4-8) were seeded at 5,000 cells/well in black flat-bottomed 96-well plates (Greiner Bio-One, 655090) in 10%LVES/
Medium 200. Following 24 h of cell growth at 37C/5%CO2, plating medium was replaced with Medium 200 containing 0.1% serum
for 24 h. Cells were then stimulated with VEGF165a (R&D Systems) at 3nM (in 0.1% serum/medium), Isoprenaline (100nM or 10mM) or
both ligands simultaneously in the presence or absence of the receptor tyrosine kinase inhibitor cediranib (1mM; Sequoia Research
Products, UK). Cediranib (1mM) was also used alone as a negative control. Following 48 h stimulation at 37C/5% CO2, cells were
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(15 min, room temperature). Nuclei were imaged using an ImageXpress Micro widefield high content imaging system (Molecular De-
vices, USA) with a 4x objective using a DAPI filter (4 sites per well, 25ms exposure time).
NFAT Luciferase Reporter Gene Assay
HEK293T cells stably expressed HaloTag-VEGFR2 or NanoLuc-VEGFR2, as well as ReLuc2P, a Firefly luciferase reporter gene
inserted downstream of the NFAT reporter to monitor NFAT-induced gene transcription (Promega Corporation, USA). Cells were
grown to 70-80% confluency and seeded in DMEM containing 10% Fetal Calf Serum at 25,000 cells per well in white 96-well plates
(Greiner Bio-One, 655089) pre-coated with poly-D-lysine (0.1mg/ml in PBS). Following 24 h of cell growth at 37C/5% CO2, plating
medium was replaced with serum free DMEM for a further 24 h. Cells were stimulated in duplicate wells with increasing concentra-
tions of VEGF165a (R&D Systems) or vehicle (serum free DMEM containing 0.1% BSA) for 5 h at 37
C/5% CO2. Assay medium was
then replaced with 50ml/well serum free DMEM and 50ml/well One-Glo Luciferase reagent (Promega Corporation, USA) and equili-
brated for 5 min to enable the reagent to react with luciferase and allow background luminescence to subside. Luminescence
was then measured by a TopCount platereader (Perkin Elmer, UK). Data were normalised to vehicle (0%) and response to 10nM
VEGF165a (100%) in each experiment and expressed as mean ± SEM. (5 independent experiments). Potency (EC50) values were
derived as described previously (Kilpatrick et al., 2017).
b-arrestin Recruitment Assays
HEK293 cells were seeded into poly-D-lysine coated white flat bottom 96 well plates and incubated for 24 h at 37C/5%CO2. At 70%
confluency, cells were transiently co-transfected with 0.04mg/well of C-terminal Venus YFP-tagged b-arrestin2 and N-terminal Halo
Tag-tagged VEGFR2, together with 0.01mg/well of C-terminal NLuc-tagged b2-adrenoceptor, using FuGENE HD at a DNA:FuGENE
ratio of 3:1, in Opti-MEMmedia. On the next day, Opti-MEMmediawas replacedwith HBSS/0.1%BSA, and 10mL furimazine at 10mM
was added in each well. Furimazine substrate was incubated for 5min at 37C. After incubation, sequential emission measurements
were taken for 4min before ligand treatment (10mM isoprenaline, 10nM VEGF165a), using a PHERAStar FS plate reader. Continuous
readings were taken every 1min for a total time of 45min, after ligand treatment, using 460nm (80nm bandpass; donor NLuc emission)
and 535nm (60nm bandpass; b-arrestin2-Venus-YFP emission) filters. Raw BRET ratios were calculated by dividing the 535nm
emission (acceptor) by the 460nm emission (donor).
Nanobody-80 Recruitment Assays
HEK293 cells stably expressing a pSIN-Nb80-GFP construct were seeded into poly-D-lysine coated white flat bottom 96 well plates
and incubated for 24h at 37C/5%CO2. At 70% confluency, cells were transiently transfected with 0.025mg/well of C-terminal NLuc-
tagged b2-adrenoceptor and 0.025mg/well HaloTag-VEGFR2 or empty vector (pcDNA3.1), using FuGENEHD at a DNA:FuGENE ratio
of 3:1, in Opti-MEM media. On the day after transfection, Opti-MEM media was replaced with HBSS/0.1% BSA, and 10mL of 10mM
furimazine substrate was added to each well, and incubated for 5min at 37C. After incubation, sequential emission measurements
were taken for 5min before ligand treatment (10mM isoprenaline, 10nM VEGF165a), using a PHERAStar FS plate reader. Continuous
readings were taken every 1min for a total time of 45min. PHERAStar FS settings used were the same described for the b-arrestin
recruitment assay.
For the isoprenaline concentration-response assay, HEK293 cells stably expressing Nb80-GFP cells were transfected as
described for the time-course assay. On the day after transfection, Opti-MEM media was replaced with HBSS/0.1%BSA and incu-
bated with increasing concentrations of isoprenaline (0.1nM to 100mM, in the presence or absence of 10nM VEGF165a; VEGF165a
treatment was added to cells co-transfected with HaloTag-VEGFR2, and not to cells transfected with the empty vector). Plates
were incubated after ligand treatment for 30min at 37C/without CO2. After incubation, 10mM furimazine substrate was added to
each well, and incubated for 5min. Sequential emission measurements were then taken using a PHERAStar FS plate reader, with
the same settings used for the b-arrestin recruitment assay.
Live Cell Confocal Imaging
HEK293 cells were seeded at 20,000 cells per well on poly-D-lysine coated Nunc Lab-Tek 8 well plates (ThermoFisher Scientific) two
days prior to imaging and cultured for 24 h at 37C/5% CO2. Cells were transiently transfected with 0.25mg per well of HaloTag-
VEGFR2, SNAP Tag-b2-adrenoceptor cDNA and grown for 24 h at 37
C/5% CO2. Additionally, double transient transfections
were performed with HaloTag- and SNAP-Tag receptor cDNA combinations (0.25mg per well total cDNA). All transfections were per-
formed using FuGENEHD in Opti-MEM according to themanufacturer’s instructions at a reagent to cDNA ratio of 3:1 and then grown
for an additional 24 h at 37C/5% CO2. On the third day, cells were incubated with 0.5mM HaloTag AF660 membrane impermeant
ligand and/or 0.5mM SNAP Tag AF488 membrane impermeant ligand for 30min at 37C/5% CO2 in DMEM. Cells were then washed
three times with HBSS followed by vehicle addition or stimulation with either 10nM VEGF165a or 10mM Isoprenaline respectively for
60min at 37C. For VEGF incubations, HBSS was supplemented with 0.1% BSA. Cells were imaged live at 37C using a Zeiss
LSM710 fitted with a 63x Plan Apochromat oil objective (1.4NA) using Argon488 (AlexaFluor488; 496-574nm band pass; 3% power)
and/or HeNe excitation (AlexaFluor647; 621-759nm bandpass; 20% power) using a 488/561/633 beamsplitter with a pinhole diam-
eter of 1 Airy unit. All images were taken at 1024x1024 pixels per frame with 8 averages.e7 Cell Chemical Biology 26, 830–841.e1–e9, June 20, 2019
Rab5 Immunolabelling
HEK293 cells were seeded at 300,000 cells/well on poly-D-lysine coated 18x18mm 1.5H coverglasses (474030-9000-000; Zeiss,
Germany) and cultured for 24 h at 37C/5% CO2. Double transient transfections were performed with HaloTag-VEGFR2 and
SNAPTag b2-adrenoceptor cDNA (3mg per well total cDNA). All transfections were performed using FuGENE HD in OptiMEM
according to themanufacturer’s instructions at a 3:1 reagent to cDNA ratio. Cells were grown for a further 24 h at 37C/5%CO2. Cells
were then incubated with 0.2mMHaloTag AF488 membrane impermeant ligand and 0.2mMSNAPTag AF647 membrane impermeant
ligand for 30min at 37C/5% CO2 in serum free DMEM/0.1% BSA. Coverslips were washed three times with HBSS/0.1% BSA and
then stimulated with vehicle, 10nM VEGF165a, 10mM isoprenaline or both VEGF165a and 10mM isoprenaline simultaneously (30min at
37C in HBSS/0.1% BSA). Cells were then washed with PBS, fixed using 3% paraformaldehyde/PBS (20min at room temperature)
and permeabilised using Triton-X-100 (0.025% in PBS). Cells were washed extensively three times with PBS between fixation and
permeabilisation. To minimize non specific binding, cells were incubated with 3% BSA/1% glycine in PBS (30min at room temper-
ature) and then blocked using 10%donkey serum in PBS (30min at room temperature). Cells were then labeled with primary antibody
diluted 1:100 in 10% donkey serum at 4C overnight (rabbit monoclonal antibody anti Rab5 (35475); New England Biolabs, USA). On
the following day, cells were washed three times with PBS and incubated with 1:500 dilution in 10%donkey serum/PBS of secondary
antibody (donkey anti rabbit IgG AlexaFluor 568 (10617183); Thermo Fisher Scientific, USA) for 1h at room temperature in the dark.
Coverslips were then washed three times in PBS and nuclei labeled using bisBenzimide H 33342 trihydrochloride (H33342; Sigma
Aldrich, USA (B2261) for 20min at room temperature. Coverslips were mounted onto microscope slides using Prolong Glass
(P36965; Thermo Fisher Scientific, USA) and imaged using a Zeiss LSM880 fitted with a PlanApochromat 63x/1.4 NA oil objective
using simultaneous multitrack settings. HaloTag VEGFR2was imaged using a Argon488 laser line (AlexaFluor488; 490-571nm band-
pass; 3% power) using a 488nm beamsplitter (1.43 Airy unit pinhole diameter, 1mm slice), Rab5 immunolabelling imaged using a
DPSS 561-10 laser line (AlexaFluor561; 570-642nm; 3% power) using a 458/561nm beamsplitter (1.21 Airy unit, 1mm slice) and
SNAP Tag b2AR imaged using HeNe633 laser line (AlexaFluor633; 638-747nm; 15% power) using a 488/561/633nm beamsplitter
(1 Airy unit, 1mm slice). All images were taken at 1024x1024 pixels per frame (0.131mm per pixel) with 8 averages.
Structured Illumination Microscopy
HEK293 cells were grown at a density of 200,000 cells on poly-D-lysine coated 18x18mm 1.5H coverglasses (474030-9000-000;
Zeiss, Germany) and cultured for 24hr at 37C/5% CO2. Double transient transfections were performed with HaloTag-VEGFR2
and SNAP-Tag b2-adrenoceptor (3mg per well total cDNA). All transfections were performed using FuGENE HD in OptiMEM accord-
ing to themanufacturer’s instructions at a reagent to cDNA ratio of 3:1. Cells were then grown for an additional 24hr at 37C/5%CO2.
On the third day, cells were incubated with 1mM HaloTag AF488 membrane impermeant ligand and/or 1mM SNAP-Surface AF647
membrane impermeant ligand for 30min at 37C/5% CO2 in DMEM/10% FCS. Cells were then washed three times with HBSS
and then stimulated with either vehicle, 10nM VEGF165a or 10mM Isoprenaline respectively for 30min at 37
C. For VEGF incubations,
HBSS was supplemented with 0.1% BSA. All cells were then fixed using 3% PFA/PBS (10min at room temperature), washed with
PBS and mounted onto slides using a 1:1 mixture of CFM3 (E17979-20; CitiFluor, USA) and Prolong Glass anti-fade reagent
(P36965; Thermo Fisher Scientific, USA). Slides were imaged using a Zeiss ELYRA PS.1 microscope using a Plan Apochromat
63x/1.4 oil DIC M27 objective with Zeiss Immersol 518F (30C) oil (Zeiss, Germany). Multitrack imaging with HaloTag-VEGFR2
imaged using bandpass 495-550 plus longpass 750 filter at 5% laser power with 150ms exposure time (28mm grating) and SNAP-
Tag b2-adrenoceptor with a long-pass 655 filter at 8% laser power with 150ms exposure time (42mm grating). All images were ac-
quired at 1024x1024 frame size over 5 rotations as a Z stack of 30-40 slices. Images were manually processed with consistent
raw scaling between and within experiments (sectioning of 100x83x93; Zen Black 2012, Zeiss, Germany). TetraSpeckTM micro-
spheres (0.1 mm; T7279, Thermo Fisher Scientific, USA) were included in each experiment to allow X/Y/Z channel alignment correc-
tion in image processing. TetraSpeckTM microspheres are stained throughout with four different fluorescent dyes, yielding excita-
tion/emission peaks of 365/430 nm (blue), 505/515 nm (green), 560/580 nm (orange), and 660/680 nm (red).
QUANTIFICATION AND STATISTICAL ANALYSIS
Analysis of ligand-binding curves was undertaken using Prism 7 software (GraphPad, San Diego, USA). Data analysis performed for
NanoBRET receptor-ligand saturation binding assays is described in detail in (Stoddart et al., 2015). Briefly, total and non-specific
saturation binding curves were simultaneously fitted using the following equation:
SB=
ðBmax3 ½LÞ
ð½L+KDÞ + ððM x ½LÞ+CÞ;
where L is the concentration of fluorescent ligand, Bmax is the maximal specific binding, KD is the dissociation constant of the
fluorescent ligand, M is the slope of the non-specific binding element and C is the intercept with the y axis.
Data analysis for receptor-receptor NanoBRET saturation assay was performed using emission measurements through two
wavelength windows. Baseline-corrected BRET ratios were calculated as shown below:
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where Cf corresponds to (emission at 535nm/emission at 460nm) for the NLuc-construct expressed alone in the same experiment.
Agonist concentration-response data were fitted using Prism 7 software (GraphPad, San Diego, USA) to the following equation:
Response=
EMAX + ½A
EC50 + ½A
Where EMAX is themaximum response, EC50 is the concentration of agonist required to produce 50%of themaximal response and (A)
is the agonist concentration.
Dissociation constants (KD) of antagonists were also calculated from the shift of the agonist concentration response curves in the
presence of a fixed concentration of antagonist using the following equation:
CR= 1+ ½B=KD
where CR (concentration ratio) is the ratio of the agonist concentration required to stimulate an identical response in the presence and
absence of the fixed concentration of antagonist (B).
Statistical analysis was largely performed on repeated experiments with matched experimental conditions using two-way ANOVA
with Dunnett’s multiple comparison tests. Mean data from 5-8 independent experiments were normally analysed. Specific informa-
tion on the number of separate experiments performed, and the number of replicates obtained in each individual experiment, is pro-
vided in each figure legend. Where time course experiments were analysed, two-way ANOVAwas used with repeated measures and
Bonferroni’s multiple comparison tests. Otherwise, one way Analysis of Variance (ANOVA) significance tests were performed using
baseline corrected BRET ratios with Tukey’s multiple comparison tests. Experiments using CRISPR/Cas9 genome-edited cells used
unpaired t-test for individual experiments and paired two-tailed t-test for the mean data obtained in each experiment. In all cases,
differences were considered significant at p < 0.05 and the data were assumed to be normally distributed.
The extent of HaloTag-VEGFR2 and SnapTag b2-adrenoceptor co-localisation in SIM images was analysed using the Fiji (ImageJ;
version 2.0.0-rc-69/1.52i) CoLoc2 analysis programme. Circular regions of interest (ROIs; 6 ROI for spectral bead images and 12-15
OIS for all experimental conditions) were placed on either the plasma membrane or intracellular regions of acquired images. Pear-
son’s correlation cofficients were obtained and averaged across all ROIs, with values then pooled and expressed as mean ± SEM.
DATA AND SOFTWARE AVAILABILITY
GraphPad Prism 7.02 (San Diego, CA, USA) was used to analyse the quantified data and produce the graphs. MetaXpress 2.0
(Molecular Devices, USA) was used to quantify HUVEC proliferation and VEGFR2 phosphorylation following high content imaging
on the IX Micro widefield platereader. SIM images were analysed for extent of fluorophore colocalisation using the Fuji (ImageJ;
version 2.0.0-rc-69/1.52i) CoLoc2 analysis programme.e9 Cell Chemical Biology 26, 830–841.e1–e9, June 20, 2019
